Mortality Rates Among Individuals Diagnosed with Pemphigus: 12-Year Experience in Tehran, Iran.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Fahimeh Abdollahimajd, Ghazal Mardani, Hamideh Moravvej, Nastaran Namazi, Zahra Razzaghi

Ngôn ngữ: eng

Ký hiệu phân loại: 181.5 Iran (Persia)

Thông tin xuất bản: Iran : Archives of Iranian medicine , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 693702

BACKGROUND: Pemphigus consists of a group of rare autoimmune bullous diseases that affect the skin and mucous membranes. Pemphigus includes three major forms: pemphigus vulgaris (PV), pemphigus foliaceus, and paraneoplastic pemphigus. Before the advent of systemic corticosteroids (SCSs), pemphigus was usually a fatal disease. Rituximab (RTX), a monoclonal antibody against the CD20+B cells has been approved for the treatment of patients with pemphigus. Previous studies have confirmed the high efficacy and safety profile of RTX in pemphigus patients. We aimed to estimate the overall mortality and causes of death among pemphigus patients who were admitted to the hospitals of Shahid Beheshti University of medical Sciences, Tehran, Iran, before and after administering RTX. METHODS: We included 480 patients admitted to Shahid Beheshti University of medical Sciences hospitals, Tehran, Iran, from October 2010 to October 2022. The diagnosis of all patients was confirmed by direct immunofluorescence and pathological studies. All variables such as age, sex, type of pemphigus, presence of comorbidities, medications, and cause of death were assessed. RESULTS: The prevalence of pemphigus was 262 (54.58%) in women and 218 (45.41%) in men ( CONCLUSION: The mean age of the disease was found to be a decade earlier than other parts of the world, with a higher preponderance of women. The most common comorbidities were hypertension and diabetes mellitus. Most deaths were due to infectious and cardiovascular diseases. Mortality rate was 1/3 in patients who received RTX compared to those who were treated with high dose corticosteroids and other immunosuppressive agents.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH